Implicit Bioscience Limited

Implicit Bioscience Limited (IBT) is a development-stage biotechnology company, engaged in development of treatments for the infectious diseases. The company develops IC14 as a clinical stage recombinant chimeric monoclonal antibody. IC14 recognizes and inhibits the function of human CD14, an essential component of the innate inflammatory response to bacterial infection. The company develops small molecule dipeptide oglufanide disodium for the preventions and treatment of hospital-acquired infections. It focuses on drug development and commercialization activities, from the life science industry, research and banking sectors. IBT operates its subsidiary, Implicit Bioscience, Inc., at Seattle, the US. The company is headquartered at Toowong in Queens Land, Australia.

Street: 
Level 1, Data 3 House
City: 
Toowong
Postcode: 
QLD 4066
Federal State : 
Australia
WebSite: 
www.implicitbioscience.com
Fax: 
61-7-37195499

Company Index Score

Current Index Score Historical Index Score
  • Implicit Bioscience Limited currently scores 50 % in the index.
  • Implicit Bioscience Limited is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Implicit Bioscience Limited is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets